ChromX Forms Diagnostic Collaboration with Boehringer Ingelheim for Lung Fibrosis

ChromX Health of Guangzhou will collaborate with Germany’s Boehringer Ingelheim to advance research on interstitial lung disease and to develop early diagnostic and intervention devices. ChromX is developing a breath-analyzing device that detects microminiature volatile organic compounds that serve as biomarkers for lung disease screening and diagnosis. BI has a novel drug candidate for idiopathic pulmonary fibrosis in a Phase III clinical trial. Interstitial lung disease (ILD) is an umbrella term used for a large group of diseases that cause fibrosis of the lungs, which can cause breathing difficulties and death. More details....

Share this with colleagues: